2014
DOI: 10.1136/annrheumdis-2014-eular.5931
|View full text |Cite
|
Sign up to set email alerts
|

AB0391 Title: Evolution of Optimized Patients in Biological Treatment with Adalimumab and Etanercept:

Abstract: Background Biological therapy has changed the management of patients with inflammatory disease, but with a great increase of pharmaceutical costs and emergence of potential adverse effects. At the end of 2011 we established an internal protocol in management and dose optimization of the patients with biological treatment. Those patients with inflammatory disease who achieve remission by clinical and laboratory parameters and show no ecographic activity (arthritis, enthesitis), receive a reduction of dose. Pati… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles